secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0000950170-23-070230
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics announces preclinical data on oral triagonist and updates on pipeline milestones
--------------------------------------------------------------------------------

- Preclinical study of incretin triagonist (GLP-1, GIP, glucagon) showed similar weight loss and lipid reduction via endoscope vs SC; no serious adverse events.
- RT-102 (teriparatide for osteoporosis) Phase 2 trial expected to start in 2024.
- Topline results from RT-111 Phase 1 (ustekinumab biosimilar) expected Q1 2024.
- RaniPill HC development expected ready for Phase 1 trials in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023070230/0000950170-23-070230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017023070230/rani-20231214.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-070230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer